U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07675187) titled 'HCC Risk and Monitoring in Patients With Type 2 Diabetes' on June 23.
Brief Summary: Liver cancer is a significant malignancy in Taiwan. With the widespread implementation of antiviral therapies, hepatitis B and C-related liver cancer has gradually declined; however, metabolic dysfunction-associated liver cancer continues to increase, particularly among patients with type 2 diabetes mellitus (T2DM) who also present with significant liver fibrosis. Current clinical guidelines lack standardized recommendations for liver cancer screening in this specific population, and data from prospective randomized controlled trials remain scarce.Th...